Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Coronavirus - Covid 19 Information Sharing Forum -- Ignore unavailable to you. Want to Upgrade?

To: ggersh who wrote (2815)	1/31/2022 11:34:09 PM
From: Broken_Clock	Respond to of 5937

January 31, 20229:30 AM HSTLast Updated 9 hours ago Future of HealthIvermectin shows ‘antiviral effect’ against COVID, Japanese company says Reuters 2 minute read Test tube with Corona virus name label is seen in this illustration taken on January 29, 2020. REUTERS/Dado Ruvic Register now for FREE unlimited access to Reuters.com TOKYO, Jan 31 (Reuters) - Japanese trading and pharmaceuticals company Kowa Co Ltd (7807.T) on Monday said that anti-parasite drug ivermectin showed an "antiviral effect" against Omicron and other coronavirus variants in joint non-clinical research. The company, which has been working with Tokyo's Kitasato University on testing the drug as a potential treatment for COVID-19, did not provide further details. The original Reuters story misstated that ivermectin was "effective" against Omicron in Phase III clinical trials, which are conducted in humans. Clinical trials are ongoing, but promotion of ivermectin as a COVID-19 treatment has generated controversy. Prominent vaccine sceptic Joe Rogan, whose podcast on Spotify has prompted protests by singers Joni Mitchell and Neil Young, has long stirred controversy with his views on the pandemic, government mandates and COVID-19 vaccines. Rogan has questioned the need for vaccines and said he used ivermectin. The drug is not approved for treatment of COVID-19 in Japan, and the U.S. Food & Drug Administration, the World Health Organization, the EU drug regulator and Merck (MRK.N), which makes the drug, have warned against its use because of a lack of scientific evidence that it has therapeutic effect. read more In guidance on its website dated September 2021, the FDA noted growing interest in the drug for preventing or treating COVID-19 in humans but said it had received multiple reports of patients who had required medical attention, including hospitalisation, after self-medicating with it. The use of ivermectin to treat COVID-19 is currently being investigated in a UK trial run by the University of Oxford. The researchers said on Monday that it was still under way and they did not want to comment further until they have results to report. read more Many potential COVID-19 treatments that showed promise in test tubes, including the antimalarial hydroxychloroquine promoted by former U.S. President Donald Trump, ultimately failed to show benefit for COVID-19 patients once studied in clinical trials. Register now for FREE unlimited access to Reuters.com Reporting by Sam Nussey and Rocky Swift Additional reporting by Jennifer Rigby in London Editing by Josephine Mason, Jan Harvey and David Goodman Our Standards: The Thomson Reuters Trust Principles.